Previous 10 | Next 10 |
Hologic has seen a strong 2021 as the pandemic has been with us longer than expected and certainly hope. While the 2022 guidance looks soft, exactly this reason will likely trigger a positive surprise. With excess earnings used to make bolt-on deals and cut debt, I remain upbeat h...
Leader in women's health to showcase clinically proven solutions across the continuum of breast and skeletal health at annual meeting Hologic, Inc. (Nasdaq: HOLX) will showcase its extensive portfolio of breast and skeletal health products, including screening and diagnostic...
Pharma/biotechnology is the most attractive healthcare subsector. Life science tools have performed the best in one year, but are overvalued now. Focus on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For November
Canada Ranks 43 out of 116 Countries and Territories on Women's Health Canada NewsWire Hologic Launches Canadian Results of Inaugural Global Women's Health Index First Study Representing the Health of 2.5 Billion Women and Girls Globally ...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
The following slide deck was published by Hologic, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Hologic, Inc. 2021 Q4 - Results - Earnings Call Presentation
Hologic (NASDAQ:HOLX) announces that its new Genius Digital Diagnostics System is now commercially available in Europe. The system is the next generation of cervical cancer screening that combines deep learning-based artificial intelligence (AI) with advanced volumetric imaging...
--Powerful artificial intelligence combined with digital imaging designed to transform the screening process-- Hologic, Inc. (Nasdaq: HOLX) announced today that its new Genius™ Digital Diagnostics System is now commercially available in Europe. The Genius Digital Diag...
Kahn Brothers’ 13F portfolio value increased from $698M to $710M this quarter. Pfizer, VOXX International, and ViewRay were increased substantially during the quarter. The portfolio continues to be very concentrated with the top five positions accounting for ~44% of the 13F...
Minerva Surgical aims to transform uterine healthcare with its minimally invasive procedures. I like the potential of the business, and despite the current growth, I wonder if the competitive strength of the solutions is strong enough. Given these dynamics, and despite modest sale...
News, Short Squeeze, Breakout and More Instantly...
2024-07-30 10:30:04 ET BTIG analyst issues NEUTRAL recommendation for HOLX on July 30, 2024 08:28AM ET. The previous analyst recommendation was Neutral. HOLX was trading at $79.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current an...
2024-07-30 09:30:03 ET RBC Capital analyst issues SECTOR PERFORM recommendation for HOLX on July 30, 2024 07:43AM ET. The previous analyst recommendation was Sector Perform. HOLX was trading at $79.64 at issue of the analyst recommendation. The overall analyst consensus ...
– Revenue of $1,011.4 Million, GAAP Diluted EPS of $0.82, and Non-GAAP Diluted EPS of $1.06; All Met or Exceeded Guidance – – Total Company Revenue Growth of 2.7%, or 3.1% in Constant Currency and 5.8% Organically excluding COVID-19; Against Growth of 18.4% in the Prior Y...